Home › Funds › KVP Capital Advisors, LP › TVTX
KVP Capital Advisors, LP position in TVTX
TRAVERE THERAPEUTICS INC · Health Care
KVP Capital Advisors, LP reported holding 39,000 shares of TVTX (TRAVERE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$2.3M, representing 1.88% of its reported portfolio and ranking #23 among its reported holdings. KVP Capital Advisors, LP has disclosed TVTX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How KVP Capital Advisors, LP's TVTX position evolved
KVP Capital Advisors, LP first disclosed a stake in TVTX in Q4 2025 at 91,000 shares (US$3.5M). Across 4 filings, KVP Capital Advisors, LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 39,000 shares valued at US$2.3M. Notable position changes include a 57% trim in Q2 2026 (shares rose 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 91.00K | $3.48M | New |
| Q1 2026 | 91.00K | $2.70M | Hold |
| Q2 2026 | 39.00K | $2.22M | Reduce |
| Q3 2026 | 39.00K | $2.30M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TVTX and 13F data
TVTX (TRAVERE THERAPEUTICS INC) is a Health Care company. 55 other funds we track also report a position in TVTX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$213.2M), Rock Springs Capital Management LP (US$129.8M), Kynam Capital Management, LP (US$117.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TVTX
- PERCEPTIVE ADVISORS LLC 3.75M sh · $213.18M · Q2 2026
- Rock Springs Capital Management LP 2.20M sh · $129.78M · Q3 2026
- Kynam Capital Management, LP 2.00M sh · $117.76M · Q3 2026
- Stephens Investment Management Group LLC 1.88M sh · $110.50M · Q3 2026
- EMERALD ADVISERS, LLC 1.56M sh · $92.06M · Q3 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 1.53M sh · $90.27M · Q3 2026
- Context Capital Management, LLC 62.70M sh · $73.14M · Q3 2026
- MPM BioImpact LLC 1.12M sh · $63.78M · Q2 2026
- EMERALD MUTUAL FUND ADVISERS TRUST 984.85K sh · $57.99M · Q3 2026
- Jones Hill Capital LP 959.63K sh · $56.50M · Q3 2026
- ARMISTICE CAPITAL, LLC 720.00K sh · $42.39M · Q3 2026
- Polar Asset Management Partners Inc. 30.50M sh · $35.91M · Q2 2026
More on KVP Capital Advisors, LP
FAQ
How long has KVP Capital Advisors, LP held TVTX?
KVP Capital Advisors, LP has disclosed TVTX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is KVP Capital Advisors, LP's current position in TVTX?
As of Q3 2026, KVP Capital Advisors, LP holds 39.00K shares of TVTX (TRAVERE THERAPEUTICS INC), valued at $2.30M, representing 1.88% of its reported portfolio and ranking #23.
Has KVP Capital Advisors, LP been buying or selling TVTX?
In the latest 13F filing (Q3 2026), KVP Capital Advisors, LP held unchanged its position in TVTX.
Which other funds hold TVTX?
Other major institutional holders of TVTX include PERCEPTIVE ADVISORS LLC, Rock Springs Capital Management LP, Kynam Capital Management, LP, among 55 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.